MedPath

Replacement of Saturated Fat in Dairy on Total Cholesterol

Not Applicable
Completed
Conditions
Hypercholesterolemia
Interventions
Dietary Supplement: MUFA-rich dairy products (UHT milk, cheese and butter)
Dietary Supplement: Conventional dairy products (UHT milk, cheese, butter)
Registration Number
NCT02089035
Lead Sponsor
University of Reading
Brief Summary

The consumption of milk and dairy products is recognised as an essential part of a healthy diet as it represents an important source of key micro- and macronutrients. Nevertheless, there is still a widespread conviction that the overall high energy density and concentration of long-chain saturated fatty acids (SFA) present in dairy have detrimental health effects, contributing to the progression of cardiovascular disease, obesity and diabetes.

Supplementation of the bovine diet with a source of MUFA, such as rapesee oil, has become an achievable strategy in order to reduce the amount of SFA present in dairy products.

The aim of this project is to observe the effects of three types of dairy products (UHT milk, cheese and butter) produced from milk derived from cows fed withhigh-oleic sunflower oil, on CVD risk biomarkers and plasma total cholesterol levels in adults with an increased risk of developing CVD. The aim is to determine whether an isoenergetic exchange of dairy products will affect vascular function and CVD biomarkers.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Mildly hypercholesterolemic: TC <5.2 and <8mmol/L
  • Age: 25-70
  • BMI: 19-32 kg/m2
  • Haemoglobin: >125g/L for women and 135g/L for men
  • Normal liver and kidney function
Exclusion Criteria
  • Milk, cheese, butter, lactose allergy
  • Drug treatment for hyperlipidaemia, hypertension, inflammation and hypercoagulation
  • Suffered myocardial infarction/stroke in the past 12months
  • Diabetic (diagnosed or fasting glucose > 7 mmol/l) or suffer from other endocrine disorders
  • Surgery in the previous 6 months
  • Excessive alcohol consumption (>28 unit/wk man; >21 unit/wk women)
  • Taking vitamin, mineral or fatty acid supplements (e.g. fish oil, calcium)
  • Pregnant, lactating, planning a pregnancy or not using effective contraceptive precautions
  • Smokers
  • Vegans
  • Anaemic
  • Planning or on a weight reduction scheme
  • Parallel participation in another intervention study
  • Participating in intensive aerobic activity for > 20 minutes 3 times per week
  • Use of anti-inflammatory medication

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
MUFA-rich dairy productsMUFA-rich dairy products (UHT milk, cheese and butter)Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period. Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis.
Conventional dairy productsConventional dairy products (UHT milk, cheese, butter)Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks. Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis.
Primary Outcome Measures
NameTimeMethod
Chronic study: Changes in fasting plasma circulating levels of total cholesterolChronic study: Baseline and week 12 for both intervention arms
Acute study: Changes in postprandial flow-mediated dilatationAcute study: 0, 180, 300 and 420 min at baseline and week 12 for both intervention arms
Secondary Outcome Measures
NameTimeMethod
Changes in vascular stiffness by Carotid Intima Media Thickness (CIMT)Chronic study: Baseline measurements (0min) for both intervention arms
Change in 24-hour ambulatory blood pressureChronic study: baseline (-1week) and week 11, 19 and 31 for 24 hours. Measurements will be recorded every 30min (7am to 10pm) and every hour (10pm-7am)
Changes in plasma circulating markers of vascular healthChronic study: Baseline and week 12 for both intervention arms. Acute study: area under the curve from 0-8 h after consumption of breakfast (0 min) and lunch (330 min) for both intervention arms
Changes in plasma circulating markers of inflammatory statusChronic study: Baseline and week 12 for both intervention arms. Acute study: area under the curve from 0-8 h after consumption of breakfast (0 min) and lunch (330 min) for both intervention arms
Changes in plasma circulating markers related to lipid metabolismChronic study: Baseline and week 12 for both intervention arms. Acute study: area under the curve from 0-8 h after consumption of breakfast (0 min) and lunch (330 min) for both intervention arms
Changes in plasma circulating markers related to insulin resistanceChronic study: Baseline and week 12 for both intervention arms. Acute study: area under the curve from 0-8 h after consumption of breakfast (0 min) and lunch (330 min) for both intervention arms
Changes in vascular stiffness by Pulse Wave Velocity (PWV)Chronic study: Baseline (0 min) and week 12 for both intervention arms
Changes in vascular stiffness by Pulse Wave Analysis (PWA)Chronic study: Baseline (0 min) and week 12 for both intervention arms
Changes in vascular stiffness by Digital Volume Pulse (DVP)Chronic study: Baseline (0 min) and week 12 for both intervention arms
Changes in monocytic cytokine production from whole blood cultureChronic and acute study: Baseline and week 12 for both intervention arms. Acute: area under the curve from 0-8 h following consumption of breakfast (0 min) and lunch (330 min) for both intervention arms
Changes in vascular reactivity by Flow Mediated Dilatation (FMD)Chronic study: Baseline and assessment at 12 weeks for each intervention arm.
Changes in anthropometric measurementsChronic study: Baseline and assessment at 12 weeks for each intervention arm.
Change in plasma phospholipid fatty acid compositionChronic and acute study: Baseline and week 12 for both intervention arms. Acute study: 0, 180, 300 and 420 min at baseline and week 12 for both intervention arms

Trial Locations

Locations (1)

Department of Food and Nutritional Sciences, University of Reading

🇬🇧

Reading, Berks, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath